< Back to previous page
Researcher
Gert De Meerleer
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Radiotherapy (Division)
Member
From1 Oct 2016 → Today
Projects
1 - 4 of 4
- Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE)From24 Sep 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Metastasis-directed therapy in castration-refractory prostate cancer: MEDCAREFrom1 Jan 2019 → 31 Dec 2022Funding: Foundations, funds and other with scientific goal
- Novel insights in the definition and treatment of high risk and oligometastatic prostate cancerFrom1 Oct 2018 → 18 Nov 2022Funding: FWO fellowships
- Traveling the prostate cancer timeline in chase of treatment paradigms Can we cure the incurable?From1 Aug 2017 → 1 Oct 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 117
- Moderate hypofractionated radiotherapy for prostate cancer: 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial.(2024)
Authors: Charlien Berghen, Gert De Meerleer
Pages: 110089 - Impact of the Standardization of Penile Cancer Care on the Quality of Care, Outcomes, and Academic-driven Centralization in a Single eUROGEN Referral Center.(2024)
Authors: Dirk De Ridder, Anne-Sophie Van Rompuy, Herlinde Dumez, Gert De Meerleer, Karolien Goffin, Hendrik Van Poppel, Steven Joniau, Maarten Albersen
Pages: 57 - 65 - A Systematic Review of the Efficacy and Toxicity of Brachytherapy Boost Combined with External Beam Radiotherapy for Nonmetastatic Prostate Cancer.(2023)
Authors: Gert De Meerleer
Pages: S2588-9311 - The Use of Soy Isoflavones in the Treatment of Prostate Cancer: A Focus on the Cellular Effects(2023)
Authors: Steven Joniau, Charlien Berghen, Kato Rans, Gert De Meerleer
- Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy(2023)
Authors: Charlien Berghen, Steven Joniau, Gert De Meerleer
Pages: 582 - 589 - Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants(2023)
Authors: Gert De Meerleer, Frank Claessens, Steven Joniau
Pages: 2065 - + - How High Should We Go for Para-aortic Lymph Node Radiation Therapy?(2023)
Authors: Gert De Meerleer
Pages: 641 - 643 - Progression-Directed Therapy in Oligoprogressive Castration-Refractory Prostate Cancer: Results of the Prospective Single-Arm Phase II MEDCARE Trial(2023)
Authors: Karolien Goffin, Gert De Meerleer
Pages: S26 - S27 - Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis(2023)
Authors: Marcella Baldewijns, Maarten Albersen, Gert De Meerleer, Benoit Beuselinck
Pages: 442 - 451 - Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus(2023)
Authors: Cédric Draulans, Gert De Meerleer, Karin Haustermans
Pages: 503 - 520